Biotech entity

Rosen Law Firm

Company

pharma is the sole category represented across all 1 tracked stories. Corcept Therapeutics Incorporated is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Rosen Law Firm, all published on February 24, 2026.

Last mentioned: Mar 21, 2026

Entity pulse

Recent coverage · Rosen Law Firm

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Rosen Law Firm

pharma is the sole category represented across all 1 tracked stories. Corcept Therapeutics Incorporated is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Biotech story that mention Rosen Law Firm, all published on February 24, 2026. Each carries 10 original sources on average.

Stories tracked
1
Sources per story
10

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Rosen Law Firm. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Lawsuit Announced

    Rosen Law Firm announces the filing of the securities fraud class action.

  2. Appellate Loss

    Teva Pharmaceuticals wins a key appeals court decision against Corcept's Korlym patents.

  3. Class Period Ends

    Conclusion of the period following corrective disclosures or market events.

  4. Class Period Begins

    Start of the period during which alleged misleading statements were made.

Stories mentioning Rosen Law Firm 1

Pharma Neutral

Corcept Therapeutics Faces Securities Fraud Lawsuit Amid Korlym Patent Battle

Rosen Law Firm has filed a class action lawsuit against Corcept Therapeutics (NASDAQ: CORT), alleging securities fraud during a period of intense patent litigation over its flagship drug, Korlym. The lawsuit covers investors who purchased shares between October 2024 and December 2025, following significant volatility linked to generic competition threats.

10 sources

Rosen Law Firm is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.